Ranolazin--ny behandling af kronisk stabil angina pectoris

Ole Ahlehoff; Peter Riis Hansen

Ranolazin--ny behandling af kronisk stabil angina pectoris

Translated title of the contribution: [Ranolazine--new treatment of chronic stable angina pectoris]

Abstract

Ranolazine sustained-release tablets were recently approved in the EU for chronic stable angina as add-on therapy when symptoms are not controlled with first-line agents. The mechanism of action is thought to involve inhibition of late sodium influx in the heart, which can reduce abnormalities of contractility and repolarisation associated with ischaemia. Ranolazine increases the exercise capacity, reduces angina, and diminishes the use of nitroglycerine. The drug has an excellent safety profile and may be a valuable addition to the treatment of chronic stable angina.

Translated title of the contribution	[Ranolazine--new treatment of chronic stable angina pectoris]
Original language	Danish
Journal	Ugeskrift for Laeger
Volume	171
Issue number	50
Pages (from-to)	3705-7
Number of pages	3
Publication status	Published - 7 Dec 2009

Cite this

@article{3e4b3b74505a46bb9d5dfad05409c710,

title = "Ranolazin--ny behandling af kronisk stabil angina pectoris",

abstract = "Ranolazine sustained-release tablets were recently approved in the EU for chronic stable angina as add-on therapy when symptoms are not controlled with first-line agents. The mechanism of action is thought to involve inhibition of late sodium influx in the heart, which can reduce abnormalities of contractility and repolarisation associated with ischaemia. Ranolazine increases the exercise capacity, reduces angina, and diminishes the use of nitroglycerine. The drug has an excellent safety profile and may be a valuable addition to the treatment of chronic stable angina.",

author = "Ole Ahlehoff and Hansen, \{Peter Riis\}",

year = "2009",

month = dec,

day = "7",

language = "Dansk",

volume = "171",

pages = "3705--7",

journal = "Ugeskrift for Laeger",

issn = "1399-4174",

publisher = "Almindelige Danske Laegeforening",

number = "50",

}

TY - JOUR

T1 - Ranolazin--ny behandling af kronisk stabil angina pectoris

AU - Ahlehoff, Ole

AU - Hansen, Peter Riis

PY - 2009/12/7

Y1 - 2009/12/7

N2 - Ranolazine sustained-release tablets were recently approved in the EU for chronic stable angina as add-on therapy when symptoms are not controlled with first-line agents. The mechanism of action is thought to involve inhibition of late sodium influx in the heart, which can reduce abnormalities of contractility and repolarisation associated with ischaemia. Ranolazine increases the exercise capacity, reduces angina, and diminishes the use of nitroglycerine. The drug has an excellent safety profile and may be a valuable addition to the treatment of chronic stable angina.

AB - Ranolazine sustained-release tablets were recently approved in the EU for chronic stable angina as add-on therapy when symptoms are not controlled with first-line agents. The mechanism of action is thought to involve inhibition of late sodium influx in the heart, which can reduce abnormalities of contractility and repolarisation associated with ischaemia. Ranolazine increases the exercise capacity, reduces angina, and diminishes the use of nitroglycerine. The drug has an excellent safety profile and may be a valuable addition to the treatment of chronic stable angina.

UR - https://www.scopus.com/pages/publications/73949110747

M3 - Tidsskriftartikel

C2 - 20003868

SN - 1399-4174

VL - 171

SP - 3705

EP - 3707

JO - Ugeskrift for Laeger

JF - Ugeskrift for Laeger

IS - 50

ER -

Ranolazin--ny behandling af kronisk stabil angina pectoris

Abstract

Other files and links

Fingerprint

Cite this